Patritumab deruxtecan
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
Trial Timeline
Nov 24, 2023 → Oct 1, 2026
NCT ID
NCT05865990About Patritumab deruxtecan
Patritumab deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Metastatic Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05865990. Target conditions include Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05620914 | Phase 2 | Withdrawn |
| NCT06941272 | Phase 1/2 | Recruiting |
| NCT06596694 | Phase 1/2 | Recruiting |
| NCT05865990 | Phase 2 | Active |
| NCT04479436 | Phase 2 | Terminated |
| NCT02980341 | Phase 1/2 | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer